1. Home
  2. NBBK vs MPLT Comparison

NBBK vs MPLT Comparison

Compare NBBK & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBBK

NB Bancorp Inc.

N/A

Current Price

$21.75

Market Cap

1.0B

Sector

N/A

ML Signal

N/A

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$18.02

Market Cap

811.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NBBK
MPLT
Founded
1892
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
811.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
NBBK
MPLT
Price
$21.75
$18.02
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$23.00
$31.00
AVG Volume (30 Days)
359.1K
166.7K
Earning Date
04-23-2026
01-01-0001
Dividend Yield
1.31%
N/A
EPS Growth
365.22
N/A
EPS
1.14
N/A
Revenue
N/A
N/A
Revenue This Year
$43.56
N/A
Revenue Next Year
$31.58
N/A
P/E Ratio
$18.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.09
$12.24
52 Week High
$22.70
$21.55

Technical Indicators

Market Signals
Indicator
NBBK
MPLT
Relative Strength Index (RSI) 48.93 53.33
Support Level $21.10 $15.78
Resistance Level $21.58 $20.09
Average True Range (ATR) 0.57 1.23
MACD -0.11 0.10
Stochastic Oscillator 18.59 52.63

Price Performance

Historical Comparison
NBBK
MPLT

About NBBK NB Bancorp Inc.

NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Share on Social Networks: